JP2008538366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538366A5 JP2008538366A5 JP2008506989A JP2008506989A JP2008538366A5 JP 2008538366 A5 JP2008538366 A5 JP 2008538366A5 JP 2008506989 A JP2008506989 A JP 2008506989A JP 2008506989 A JP2008506989 A JP 2008506989A JP 2008538366 A5 JP2008538366 A5 JP 2008538366A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pain
- group
- withdrawal
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000011117 substance-related disease Diseases 0.000 claims 10
- 208000002193 Pain Diseases 0.000 claims 8
- 206010013663 drug dependence Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 208000007848 Alcoholism Diseases 0.000 claims 4
- 206010013654 Drug abuse Diseases 0.000 claims 4
- 206010020853 Hypertonic bladder Diseases 0.000 claims 4
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 4
- 108010025083 TRPV1 receptor Proteins 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 208000020629 overactive bladder Diseases 0.000 claims 4
- 230000036407 pain Effects 0.000 claims 4
- RLWGDRLXZSLGHV-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[(4-tert-butylphenyl)methyl]urea Chemical compound C1=C(OCCN)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(C)(C)C)=C1 RLWGDRLXZSLGHV-UHFFFAOYSA-N 0.000 claims 2
- OUEKLNJUMVZULZ-UHFFFAOYSA-N 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-n-[3-(3,4-dimethylphenyl)propyl]acetamide;hydron;chloride Chemical compound Cl.C1=C(OCCN)C(OC)=CC(CC(=O)NCCCC=2C=C(C)C(C)=CC=2)=C1 OUEKLNJUMVZULZ-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 2
- 206010006482 Bronchospasm Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 claims 2
- 206010015946 Eye irritation Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020710 Hyperphagia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- OPZKBPQVWDSATI-KHPPLWFESA-N N-Vanillyloleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-KHPPLWFESA-N 0.000 claims 2
- QVLMCRFQGHWOPM-ZKWNWVNESA-N N-arachidonoyl vanillylamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC1=CC=C(O)C(OC)=C1 QVLMCRFQGHWOPM-ZKWNWVNESA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000004880 Polyuria Diseases 0.000 claims 2
- 206010062519 Poor quality sleep Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 206010040880 Skin irritation Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 claims 2
- 108050004388 Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 206010001584 alcohol abuse Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 208000025746 alcohol use disease Diseases 0.000 claims 2
- 208000029650 alcohol withdrawal Diseases 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 230000000949 anxiolytic effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000007885 bronchoconstriction Effects 0.000 claims 2
- 229960002504 capsaicin Drugs 0.000 claims 2
- 235000017663 capsaicin Nutrition 0.000 claims 2
- 210000000748 cardiovascular system Anatomy 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000035619 diuresis Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 231100000013 eye irritation Toxicity 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 208000021760 high fever Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 238000002690 local anesthesia Methods 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000008450 motivation Effects 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- OPZKBPQVWDSATI-UHFFFAOYSA-N oleoyl vanillylamide Natural products CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-UHFFFAOYSA-N 0.000 claims 2
- 229950010717 olvanil Drugs 0.000 claims 2
- 229940005483 opioid analgesics Drugs 0.000 claims 2
- 235000020830 overeating Nutrition 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 claims 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 claims 2
- 229940073454 resiniferatoxin Drugs 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 230000036556 skin irritation Effects 0.000 claims 2
- 231100000475 skin irritation Toxicity 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005018191.0 | 2005-04-19 | ||
| DE102005018191A DE102005018191A1 (de) | 2005-04-19 | 2005-04-19 | Substituierte zyklische Harnstoff-Derivate und deren Verwendung zur Herstellung von Arzneimitteln |
| PCT/EP2006/003519 WO2006111346A1 (de) | 2005-04-19 | 2006-04-18 | Substituierte zyklische harnstoff-derivate und deren verwendung als vanilloid-rezeptor 1 modulatoren |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008538366A JP2008538366A (ja) | 2008-10-23 |
| JP2008538366A5 true JP2008538366A5 (https=) | 2013-02-14 |
| JP5214436B2 JP5214436B2 (ja) | 2013-06-19 |
Family
ID=36764431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008506989A Expired - Fee Related JP5214436B2 (ja) | 2005-04-19 | 2006-04-18 | 置換された環状尿素誘導体及び医薬の製造へのその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8207182B2 (https=) |
| EP (1) | EP1874733B1 (https=) |
| JP (1) | JP5214436B2 (https=) |
| CA (1) | CA2605144C (https=) |
| DE (1) | DE102005018191A1 (https=) |
| ES (1) | ES2386796T3 (https=) |
| PL (1) | PL1874733T3 (https=) |
| WO (1) | WO2006111346A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008029168A2 (en) * | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| US8557872B2 (en) | 2008-01-28 | 2013-10-15 | Amorepacific Corporation | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| US8691855B2 (en) | 2008-07-02 | 2014-04-08 | Amorepacific Corporation | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same |
| WO2011018790A1 (en) * | 2009-08-12 | 2011-02-17 | Technion Research & Development Foundation Ltd. | Polycyclic compounds, termed calixurenes, and uses thereof |
| US8815265B2 (en) | 2010-06-30 | 2014-08-26 | Avon Products, Inc. | Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds |
| KR102505374B1 (ko) * | 2016-10-06 | 2023-03-02 | 닛산 가가쿠 가부시키가이샤 | 디아민, 중합체, 액정 배향제, 액정 배향막 및 액정 표시 소자 |
| US20240287019A1 (en) * | 2021-06-07 | 2024-08-29 | Kinki University | T-type calcium channel blocker |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670368A1 (de) * | 1966-07-16 | 1970-11-05 | Cassella Farbwerke Mainkur Ag | Verfahren zur Herstellung aralkylsubstituierter Lactame und Cyclischer Harnstoffe |
| JPS588503B2 (ja) * | 1974-12-27 | 1983-02-16 | 富士写真フイルム株式会社 | カラ−シヤシンカンコウザイリヨウ |
| JPS58203976A (ja) * | 1982-05-24 | 1983-11-28 | Sumitomo Chem Co Ltd | ベンズイミダゾリン−２−チオン誘導体の製造法 |
| JPS63170011A (ja) * | 1987-01-07 | 1988-07-13 | Mitsubishi Monsanto Chem Co | アミド系樹脂成形品およびその製造法 |
| GB8724912D0 (en) | 1987-10-23 | 1987-11-25 | Wellcome Found | Indole derivatives |
| DE4300912A1 (de) * | 1993-01-15 | 1994-07-21 | Merck Patent Gmbh | Chinazolinderivate |
| FR2722190B1 (fr) * | 1994-07-05 | 1996-10-04 | Sanofi Sa | Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant |
| US5612363A (en) * | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
| WO1997008150A1 (en) * | 1995-08-22 | 1997-03-06 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors |
| AU2001280229B2 (en) * | 2000-08-21 | 2006-12-07 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| WO2004103281A2 (en) * | 2003-05-16 | 2004-12-02 | Georgetown University | Vanilloid receptor antagonists, and methods of making and using them |
| US20090264650A1 (en) | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
-
2005
- 2005-04-19 DE DE102005018191A patent/DE102005018191A1/de not_active Withdrawn
-
2006
- 2006-04-18 EP EP06742597A patent/EP1874733B1/de not_active Expired - Lifetime
- 2006-04-18 PL PL06742597T patent/PL1874733T3/pl unknown
- 2006-04-18 ES ES06742597T patent/ES2386796T3/es not_active Expired - Lifetime
- 2006-04-18 CA CA2605144A patent/CA2605144C/en not_active Expired - Fee Related
- 2006-04-18 WO PCT/EP2006/003519 patent/WO2006111346A1/de not_active Ceased
- 2006-04-18 JP JP2008506989A patent/JP5214436B2/ja not_active Expired - Fee Related
-
2007
- 2007-10-19 US US11/875,570 patent/US8207182B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526061A5 (https=) | ||
| JP2010523726A5 (https=) | ||
| JP2007514637A5 (https=) | ||
| JP2008540592A5 (ja) | 置換されたスピロ化合物及び鎮痛剤の製造へのその使用 | |
| JP2009543825A5 (https=) | ||
| JP2008538366A5 (https=) | ||
| JP2009500427A5 (https=) | ||
| JP2007508361A5 (https=) | ||
| EP2746291A3 (en) | Pulmonary formulation comprising an immunoglobulin single variable domain which binds to TNFR1 | |
| JP2008543776A5 (https=) | ||
| WO2007104789A3 (en) | Amylin derivatives | |
| WO2009042922A3 (en) | Peptide-peptidase inhibitor conjugates and methods of making and using same | |
| TW200738633A (en) | Diaryl piperidines as CB1 modulators | |
| JP2007523178A5 (https=) | ||
| JP2009522339A5 (https=) | ||
| WO2009064460A3 (en) | Gastrointestinal delivery systems | |
| HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida | |
| JP2008524262A5 (https=) | ||
| JP2011512374A5 (https=) | ||
| JP2009538870A5 (https=) | ||
| MA38847A1 (fr) | Formulation médicamenteuse à libération retardée | |
| WO2008120761A1 (ja) | ヘテロアリール誘導体 | |
| JP2011515430A5 (https=) | ||
| DE502005010170D1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
| JP2011515429A5 (https=) |